Oracle Recognized as a Leader in 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services
Oracle (NYSE:ORCL) has been named a leader in the 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services. The company's pharmacovigilance (PV) division demonstrates strong market dominance with 60% market share in PV software and projects 20% annual revenue growth over the next three years.
Oracle's comprehensive ecosystem includes the Safety One Platform, Oracle Real-World Data, Health Data Intelligence platform, and Oracle Cloud Infrastructure AI Services. The company has secured 100 new PV customers in the past year and maintains over 400 direct PV customers. Notably, Oracle's Argus platform processes 70% of all drug ICSRs and 90% of vaccine ICSRs reported to the FDA since 2017.
Oracle (NYSE: ORCL) è stata nominata leader nel 2025 IDC MarketScape per soluzioni e servizi di consulenza tecnologica worldwide Life Science R&D Pharmacovigilance. La sua divisione farmacovigilance (PV) mostra una forte supremazia di mercato con una quota di mercato del 60% nel software PV e prevede una crescita annua dei ricavi del 20% nei prossimi tre anni.
L'ecosistema completo di Oracle comprende la Safety One Platform, Oracle Real-World Data, la Health Data Intelligence platform e Oracle Cloud Infrastructure AI Services. Nell'ultimo anno Oracle ha acquisito 100 nuovi clienti PV e mantiene oltre 400 clienti PV diretti. In particolare, la piattaforma Argus di Oracle elabora il 70% di tutti gli ICSR di farmaci e il 90% degli ICSR di vaccini riportati alla FDA dal 2017.
Oracle (NYSE: ORCL) ha sido designada líder en el 2025 IDC MarketScape para soluciones y servicios de consultoría tecnológica mundial en el ámbito de la farmacovigilancia en I+D de ciencias de la vida. La división de farmacovigilancia (PV) de la compañía demuestra una fuerte dominancia en el mercado con una cuota de mercado del 60% en software PV y se prevé un crecimiento anual de los ingresos del 20% durante los próximos tres años.
El ecosistema detallado de Oracle incluye la Safety One Platform, Oracle Real-World Data, la Health Data Intelligence platform y Oracle Cloud Infrastructure AI Services. En el último año ha conseguido 100 nuevos clientes PV y mantiene más de 400 clientes PV directos. Cabe destacar que la plataforma Argus de Oracle procesa el 70% de todos los ICSR de fármacos y el 90% de los ICSR de vacunas reportados a la FDA desde 2017.
Oracle (NYSE:ORCL)은 세계적 Life Science R&D Pharmacovigilance 기술 솔루션 및 컨설팅 서비스에 대한 2025 IDC MarketScape에서 선두주자로 선정되었습니다. PV 부문은 PV 소프트웨어에서 시장 점유율 60%의 강력한 시장 지배력을 보이며 향후 3년간 매출이 연평균 20% 성장할 것으로 예상됩니다.
Oracle의 포괄적 생태계에는 Safety One Platform, Oracle Real-World Data, Health Data Intelligence 플랫폼, 그리고 Oracle Cloud Infrastructure AI Services가 포함됩니다. 지난 해 PV 신규 고객 100곳을 확보했고 직접 PV 고객 400곳 이상을 유지하고 있습니다. 특히 Oracle의 Argus 플랫폼은 약물 ICSR의 70%를 처리하고 FDA에 보고된 백신 ICSR의 90%를 처리해 왔습니다(2017년부터).
Oracle (NYSE:ORCL) a été désignée comme leader dans le 2025 IDC MarketScape pour les solutions et services de conseil technologique mondiaux en pharmacovigilance R&D dans les sciences de la vie. La division pharmacovigilance (PV) de l'entreprise démontre une forte domination du marché avec une part de marché de 60% dans les logiciels PV et prévoit une croissance annuelle des revenus de 20% au cours des trois prochaines années.
L'écosystème complet d'Oracle comprend la Safety One Platform, Oracle Real-World Data, la Health Data Intelligence platform et Oracle Cloud Infrastructure AI Services. Au cours de l'année passée, Oracle a gagné 100 nouveaux clients PV et compte plus de 400 clients PV directs. Notamment, la plateforme Argus d'Oracle traite 70% de tous les ICSR de médicaments et 90% des ICSR de vaccins signalés à la FDA depuis 2017.
Oracle (NYSE:ORCL) wurde als führendes Unternehmen im 2025 IDC MarketScape für weltweite Life-Science-F&E-Verfahren zur Pharmacovigilance-Technologie-Lösungen und Beratungsdienste anerkannt. Die PV-Sparte des Unternehmens zeigt eine starke Marktdominanz mit 60% Marktanteil bei PV-Software und prognostiziert ein jährliches Umsatzwachstum von 20% in den nächsten drei Jahren.
Oracles umfassendes Ökosystem umfasst die Safety One Platform, Oracle Real-World Data, Health Data Intelligence Platform und Oracle Cloud Infrastructure AI Services. Im vergangenen Jahr konnte das Unternehmen 100 neue PV-Kunden gewinnen und hält über 400 direkte PV-Kunden. Bemerkenswert ist, dass Oracles Argus-Plattform 70% aller Drug-ICSRs verarbeitet und 90% der Impfstoff-ICSRs, die der FDA seit 2017 gemeldet wurden, verarbeitet.
Oracle (NYSE:ORCL) تم اختيارها كقائد في IDC MarketScape 2025 لحلول وتقديم الاستشارات في تكنولوجيا مراقبة السلامة الدوائية (Pharmacovigilance) لأبحاث وتطوير علوم الحياة على مستوى العالم. قسم PV في الشركة يُظهر سيطرة قوية على السوق مع حصة سوقية قدرها 60% في برامج PV ويتوقع نموًا في الإيرادات سنويًا بنسبة 20% خلال السنوات الثلاث المقبلة.
يشمل النظام البيئي الشامل لدى Oracle Safety One Platform وOracle Real-World Data وHealth Data Intelligence platform وOracle Cloud Infrastructure AI Services. في العام الماضي حققت الشركة 100 عميل PV جديد وتبقي على أكثر من 400 عميل PV مباشر. ومن الجدير بالذكر أن منصة Argus لدى Oracle تعالج حوالي 70% من جميع ICSR للأدوية و90% من ICSR اللقاحات المبلغ عنها إلى FDA منذ 2017.
Oracle (NYSE:ORCL) 已被评为 2025 IDC MarketScape 全球生命科学研发药物警戒技术解决方案与咨询服务领域的领导者。公司的药物警戒（PV）部门在市场上展现出强大的主导地位，在 PV 软件领域的市场份额达到 60%，未来三年的营业收入预计将实现 20% 的年增长率。
Oracle 的完整生态系统包括 Safety One Platform、Oracle Real-World Data、Health Data Intelligence 平台，以及 Oracle Cloud Infrastructure AI Services。过去一年新增 100 名 PV 客户，直接 PV 客户超过 400 名。值得注意的是，Oracle 的 Argus 平台自 2017 年以来处理了向 FDA 报告的 药物 ICSR 的 70% 与 疫苗 ICSR 的 90%。
- Dominant 60% market share in pharmacovigilance software market
- Projected 20% annual revenue growth in PV division for next 3 years
- Addition of 100 new PV customers in past 12 months
- Controls 70% of drug ICSRs and 90% of vaccine ICSRs reported to FDA
- Extensive experience with over 100,000 clinical trials with PV focus
- None.
"By bringing together its solutions for safety, data, and intelligence, Oracle is building a connected ecosystem for precision PV," said Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology, IDC. "This approach, combined with their regulatory expertise and extensive customer base, positions Oracle to guide the industry towards more proactive and intelligent drug safety management."
"This recognition from the IDC MarketScape further validates Oracle's pivotal role in advancing drug safety innovation and the significant investments we have made in R&D to help our customers more swiftly and safely get life-saving treatments to market," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "We further believe Oracle's Safety One platform, combined with our deep domain and AI expertise, is equipping organizations to confidently navigate the complexities of modern pharmacovigilance, helping to ensure they are future-ready for evolving regulatory landscapes and safety challenges."
The report noted, "Oracle has been providing PV technology solutions and consulting services for close to three decades. It estimates that its PV revenue will grow by
By continuously delivering advanced, AI-powered solutions and comprehensive services, Oracle empowers its customers to optimize pharmacovigilance operations and uphold the highest standards of patient safety.
To access the 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services excerpt visit: https://www.oracle.com/life-sciences/safety-solutions/
About IDC MarketScape
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
About Oracle Life Sciences
Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years of experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements--empowering the life sciences industry to improve patient outcomes. Learn more at www.oracle.com/life-sciences.
About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.
Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company--ushering in the new era of cloud computing.
1 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services (doc # US53669225, July 2025) - https://www.oracle.com/life-sciences/safety-solutions/
View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-recognized-as-a-leader-in-2025-idc-marketscape-for-worldwide-life-science-rd-pharmacovigilance-technology-solutions-and-consulting-services-302569964.html
SOURCE Oracle
FAQ
What is Oracle's market share in the pharmacovigilance software market?
How many new pharmacovigilance customers did Oracle acquire in 2025?
What is Oracle's projected growth rate for their pharmacovigilance revenue?
What key technologies does Oracle use for pharmacovigilance?
How many clinical trials has Oracle supported with pharmacovigilance focus?
